VEDOKIDS

VEDOKIDS

Contact

 If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description
This study aims to prospectively explore the real life short and longer term outcomes of Vedolizumab in pediatric inflammatory bowel disease and to develop a prediction model for treatment success based on Vedolizumab trough levels and other clinical and laboratory markers. Children under 18 years of age that have been diagnosed with IBD and their physician is starting treatment with Vedolizumab may be eligible.

Eligibility and criteria
IRB Number:
18-015108
Eligible age range:
Any years - 18 years
Clinical trial phase:
N/A
Official title:
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases including Drug Levels: a Multi-Center Prospective Pan- European Cohort Study (P-ECCO and ESPGHAN)

What to expect

Related specialties
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.